A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.

Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD
Am J Clin Oncol. 2008 31 (5): 413-6

PMID: 18838875 · DOI:10.1097/COC.0b013e318168ef2a

MeSH Terms (15)

Aged Antineoplastic Combined Chemotherapy Protocols Camptothecin Disease-Free Survival Epirubicin Female Humans Irinotecan Male Maximum Tolerated Dose Middle Aged Neoplasms Salvage Therapy Survival Rate Treatment Outcome

Connections (3)

This publication is referenced by other Labnodes entities: